Table 3.
BMI <22 |
25–29.9
|
30–34.9
|
35–39.9
|
≥40 kg/m2
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Outcomes | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value | HR | 95% CI | P-value |
All-cause mortality | |||||||||||||||
Age and sex adjusted | 1.28 | 1.03–1.60 | 0.029 | 0.80 | 0.70–0.92 | 0.001 | 0.83 | 0.72–0.96 | 0.011 | 0.94 | 0.77–1.14 | 0.518 | 1.02 | 0.77–1.35 | 0.876 |
Full adjustment | 1.29 | 1.01–1.65 | 0.038 | 0.79 | 0.68–0.91 | 0.002 | 0.75 | 0.61–0.93 | 0.008 | 0.65 | 0.46–0.92 | 0.014 | 0.81 | 0.50–1.32 | 0.395 |
CV mortality | |||||||||||||||
Age and sex adjusted | 1.31 | 0.99–1.74 | 0.056 | 0.78 | 0.66–0.93 | 0.006 | 0.79 | 0.66–0.96 | 0.015 | 0.80 | 0.62–1.04 | 0.099 | 0.96 | 0.67–1.38 | 0.833 |
Full adjustment | 1.35 | 1.00–1.83 | 0.048 | 0.81 | 0.67–0.98 | 0.033 | 0.69 | 0.53–0.89 | 0.005 | 0.59 | 0.38–0.92 | 0.020 | 0.68 | 0.36–1.26 | 0.217 |
Primary composite endpointa | |||||||||||||||
Age and sex adjusted | 1.13 | 0.90–1.42 | 0.278 | 0.86 | 0.75–0.98 | 0.023 | 0.79 | 0.68–0.91 | 0.001 | 0.87 | 0.72–1.06 | 0.163 | 0.83 | 0.63–1.10 | 0.189 |
Full adjustment | 1.24 | 0.97–1.58 | 0.090 | 0.88 | 0.76–1.02 | 0.089 | 0.70 | 0.57–0.85 | 0.001 | 0.69 | 0.49–0.96 | 0.029 | 0.68 | 0.42–1.11 | 0.122 |
Expanded composite endpointb | |||||||||||||||
Age and sex adjusted | 0.95 | 0.78–1.16 | 0.637 | 0.96 | 0.87–1.07 | 0.449 | 0.98 | 0.88–1.10 | 0.763 | 1.03 | 0.89–1.19 | 0.718 | 0.86 | 0.70–1.07 | 0.190 |
Full adjustment | 1.03 | 0.83–1.27 | 0.798 | 0.95 | 0.85–1.070 | 0.421 | 0.86 | 0.74–1.01 | 0.072 | 0.86 | 0.66–1.12 | 0.254 | 0.78 | 0.53–1.12 | 0.217 |
Full adjustment for age, sex, ever smoker, previous cardiovascular event, LDL, HbA1c, eGFR, allocation to glargine, allocation to omega 3 fatty acid, duration of DM, waist circumference, systolic blood pressure, ACE or ARB medication, beta-blocker medication, statin medication. Hip circumference, hypertension and diastolic blood pressure were not included in the model because of collinearity.
Primary composite endpoint: composite of first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
Expanded composite endpoint: composite of first occurrence of these three outcomes or revascularization or heart failure hospitalization.